← Back to Analyst Consensus 
ALGS Buy
Aligos Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 4, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| May 28, 2026 | Lake Street | initiate | — → Buy | — | 47% |
| May 21, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Mar 26, 2026 | WestPark Capital | initiate | — → Buy | — | 51% |
| Mar 11, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jan 7, 2026 | UBS | initiate | — → Buy | $20 | 54% |
| Sep 12, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
| Mar 31, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $70 | 44% |
| Mar 11, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $70 | 44% |
| Nov 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Oct 23, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Sep 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Aug 19, 2024 | HC Wainwright & Co. | initiate | — → Buy | $75 | 44% |
| Jan 17, 2023 | Piper Sandler | maintain | — → Overweight | $7 | 54% |
| Jan 6, 2023 | Piper Sandler | upgrade | Neutral → Overweight | $3 | 54% |
| Jan 6, 2023 | Jefferies | upgrade | Hold → Buy | $3 | 52% |
| Nov 3, 2022 | SVB Leerink | maintain | — → Market Perform | $2 | — |
| May 5, 2022 | SVB Leerink | downgrade | Outperform → Market Perform | $3 | — |
| Mar 23, 2022 | SVB Leerink | maintain | — → Outperform | $7 | — |
| Mar 23, 2022 | Piper Sandler | downgrade | Overweight → Neutral | $4 | 54% |
| Mar 11, 2022 | Piper Sandler | maintain | — → Overweight | $15 | 54% |
| Mar 11, 2022 | SVB Leerink | maintain | — → Outperform | $11 | — |
| Feb 16, 2022 | SVB Leerink | maintain | — → Outperform | $10 | — |
| Jan 7, 2022 | JP Morgan | downgrade | Overweight → Neutral | $12 | 55% |
| Jan 7, 2022 | SVB Leerink | maintain | — → Outperform | $15 | — |
| Sep 9, 2021 | SVB Leerink | initiate | — → Outperform | $29 | — |
| Nov 10, 2020 | Jefferies | initiate | — → Buy | $26 | 52% |
| Nov 10, 2020 | JP Morgan | initiate | — → Overweight | $33 | 55% |
| Nov 10, 2020 | Piper Sandler | initiate | — → Overweight | $35 | 54% |
Price Target Trend
Apr 14, 2026 Latest: $52.38 Oct 23, 2026
EPS Estimates
+1y $-5.25
Lo: $-7.18 Hi: $-2.78
7 analysts ▲1
0q $-2.53
Lo: $-3.04 Hi: $-2.06
6 analysts ▲2
+1q $-1.73
Lo: $-2.59 Hi: $-0.69
6 analysts ▲3
0y $-6.52
Lo: $-8.03 Hi: $-4.44
6 analysts ▲3
Cross-Platform Signals
No cross-platform signals in the last 90 days